REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Questions & Help
10

Anyone Tried CJC-1295 (with DAC) for Recovery?

Casey Baldwin·about 2 months ago
Has anyone here used CJC-1295 (with DAC) specifically for recovery purposes? I am an athlete dealing with nagging overuse issues and looking for something to support faster recovery between training sessions. What I have read suggests CJC-1295 (with DAC) could help, but most reports I find online are either obviously shilling or so vague they are useless. Looking for detailed real-world experiences from people who tracked their recovery metrics. Specific things I am interested in: - How long until recovery benefits became noticeable? - Did the benefits persist after stopping? - Any impact on sleep quality? - Side effects that affected training?

Comments (6)

Shay FischerDEMO·about 2 months ago

This thread has been incredibly helpful for understanding CJC-1295 (with DAC). I have been on the fence about starting for months and reading detailed real-world experiences like these has been more useful than any blog post or article I have found. The fact that most reports here are moderate rather than extreme actually increases my confidence.

6
Micah GoodmanDEMO·about 2 months ago

One thing I wish more CJC-1295 (with DAC) discussions covered is the discontinuation experience. What happens when you stop? In my case, the benefits gradually faded over about 3-4 weeks after stopping. Sleep was the first thing to return to baseline. Recovery improvements lasted a bit longer. Worth knowing for planning protocol duration.

2
Scout BarkerDEMO·about 2 months ago

Great point about bloodwork. I ran comprehensive panels at baseline, 6 weeks, and 12 weeks during my CJC-1295 (with DAC) protocol. The most informative markers for me were inflammatory markers and IGF-1 levels. Would strongly recommend anyone running CJC-1295 (with DAC) to invest in proper monitoring.

3
Raven DaltonDEMO·about 2 months ago

The timeline you describe is spot on with my CJC-1295 (with DAC) experience. I also want to emphasize the importance of injection technique. When I switched from 30-gauge to 29-gauge needles and slowed my injection speed, the site irritation essentially disappeared. Small details make a big difference in compliance.

4
Kendall HarmonDEMO·about 2 months ago

Following up on my earlier comment about CJC-1295 (with DAC). I am now 4 weeks past the end of my protocol and wanted to report that about 60 percent of the benefits seem to have persisted. Sleep is still better than baseline, recovery is somewhere between pre-protocol and on-protocol levels. Encouraging for the sustainability question.

5
Sawyer FergusonDEMO·about 2 months ago

Great write-up. I have been running a similar CJC-1295 (with DAC) protocol and my experience aligns pretty closely with what you described. The sleep improvements were the first thing I noticed too, usually around week 2-3. One thing I would add is that I found keeping injection sites consistent with rotation between 4-5 spots worked better than random placement. Less irritation overall.

6

Sign in to comment.